CJC-1295 (No DAC) + Ipamorelin

CJC-1295 (No DAC) + Ipamorelin

CJC-1295 (No DAC) + Ipamorelin is a research-grade peptide blend combining two complementary growth hormone secretagogues for preclinical investigation of the GH/IGF-1 axis. CJC-1295 (No DAC) is a GHRH analogue that stimulates pituitary somatotrophs, while Ipamorelin is a selective ghrelin receptor (GHS-R1a) agonist that promotes GH release through a distinct, independent pathway. Together, they are studied for their synergistic effects on pulsatile GH secretion in experimental models.

Mechanism of Action

CJC-1295 (No DAC) activates the GHRH receptor on pituitary somatotrophs, stimulating GH synthesis and release. Ipamorelin acts on the ghrelin receptor (GHS-R1a) to amplify GH secretion through a separate intracellular signalling cascade involving phospholipase C and protein kinase C. The combination produces additive or synergistic GH release by engaging both receptor pathways simultaneously, while Ipamorelin's high selectivity minimises off-target effects on cortisol and prolactin secretion observed with earlier GHRPs.

Research Applications

• Synergistic GH secretagogue pharmacology studies
• GH/IGF-1 axis and pituitary function investigation
• Ghrelin receptor (GHS-R1a) signalling research
• Anabolic and metabolic regulation modelling
• Combination peptide therapy and receptor crosstalk studies

Specifications

• Composition: CJC-1295 (No DAC) + Ipamorelin peptide blend
• Purity: ≥98%
• Form: Lyophilised powder
• Storage: -20°C
• Shelf Life: 24 months

Individual Components

Also available separately: CJC-1295 (No DAC) and Ipamorelin. For sustained GH release research, see CJC-1295 (With DAC). For comparative GHRP research, see GHRP-6 Acetate.

This peptide blend is supplied as a lyophilised powder and requires reconstitution with Bacteriostatic Water prior to use.

This product is intended for legitimate laboratory and analytical research use only. Not for human use, veterinary use, or consumer use. Not for diagnostic or therapeutic purposes.